A recent study published in Oncotarget found that cancer drug affordability is correlated with wealth, with the US having the highest average monthly price per patented drug. This has led to a financial burden on both society and patients, with individuals diagnosed with cancer being 2.7 times more likely to declare bankruptcy.
A study published in Oncotarget identifies a key step in the modification of Snail1, which can alter its structure and function to promote prostate cancer cell migration. The researchers found that preventing this modification can abolish the migratory and invasive properties of human prostate cancer cells.
Researchers at Harvard Medical School have discovered a novel therapeutic strategy to treat drug-resistant thyroid cancers by combining vemurafenib with palbociclib, a CDK4/6 inhibitor. The treatment was shown to induce stronger cell death than when used alone, offering new hope for patients with papillary thyroid carcinoma.
Oncotarget has increased its publishing frequency to two issues per week, making scientific results widely available through various indexes and archives. This move aims to accelerate indexing processes and provide rapid access to medical researchers, practitioners, and the general public.
Four biomedical researchers from Aligarh Muslim University, National Institute of Immunology India, and University of Torino presented groundbreaking studies on kidney cancer treatment, chemoresistance, and asbestos-related tumors at FCS 2017. Oncotarget's travel grants enabled their participation in the conference.
Researchers have identified a potential therapeutic target for aggressive breast cancer cells lacking estrogen receptor alpha, but expressing estrogen receptor beta. Estrogen or estrogen-like chemicals can slow tumor growth and even cause regression in these cells, which could lead to new treatment options.